(Press-News.org) A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab1 significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.
The trial results, published today in The Lancet, are good news for non-small cell lung cancer patients who are not eligible for standard of care platinum-based chemotherapy, due to concerns about their ability to withstand the treatment.
Lung cancer is the leading cause of cancer death worldwide, with around 2.2 million new cases and 1.8 million deaths a year. The majority of patients present with advanced stage non-small cell lung cancer (NSCLC) 2.
For the fittest patients with advanced stage NSCLC, first-line immunotherapy with or without platinum-based doublet chemotherapy (PDC) is now established as the standard of care treatment. This follows several randomised trials that were limited to ‘fit’ participants with a median age of 65 or younger and were able to tolerate PDC.
However, more than 40% of advanced stage NSCLC patients are in poor health and are often elderly with significant medical co-morbidities. Treatment with standard PDC is not suitable for many of these patients because of poor tolerance or toxicity concerns, leaving them with limited treatment options. They are frequently treated with less effective single-agent chemotherapy or offered best supportive care.
Currently, most treatment guidelines do not recommend immunotherapy treatment due to lack of randomised results to indicate that it is safe, well tolerated and increases overall survival3 for this poor prognosis population.
Sponsored by Roche, this is the first reported randomised phase III trial of first-line immunotherapy treatment with atezolizumab (also known as Tecentriq) in an advanced NSCLC population deemed unfit for standard platinum-chemotherapy4. The trial sought to establish the efficacy, safety and overall survival rate of first-line immunotherapy treatment with atezolizumab compared with single-agent chemotherapy in advanced stage NSCLC patients. Patients were randomised 2:1, with 302 patients receiving atezolizumab and 151 receiving single-agent chemotherapy.
The study showed that atezolizumab significantly improved overall survival and resulted in a clinically meaningful long-term survival benefit, with twice as many patients (24%) who were treated with atezolizumab remaining alive at two years compared to those treated with chemotherapy (12%), despite over 50% of chemotherapy patients who were still alive at two years receiving subsequent immunotherapy.
Professor Siow Ming Lee (UCL Cancer Institute and UCL Hospitals), who chaired the study Steering Committee and conceptualised the study design, said: “For over two decades, clinical trials have failed to provide significant therapeutic benefits to older NSCLC patients with poor health who are unfit for standard platinum doublet chemotherapy. IPSOS is the first randomised trial to show that immunotherapy treatment with first-line atezolizumab treatment significantly improves overall survival compared to single-agent chemotherapy for these poor prognosis patients, with twice as many remaining alive at two years. The treatment also resulted in stabilised or improved health-related quality of life measures, and no new safety concerns were identified.”
This trial was supported by Roche.
Contact details:
Dr Matt Midgley
UCL Media Relations
+44 (0)20 7679 9064
m.midgley@ucl.ac.uk
Notes to Editors:
1 Atezolizumab (also known as Tecentriq) is a type of immunotherapy known as a check-point inhibitor, which helps make cancer cells more vulnerable to attack by harnessing the body’s own immune system. It does this by blocking the activity of a molecule called PD-L1, thereby allowing T-cells (white blood cells that help your body fight disease) to attack and destroy cancer cells.
2 Advanced cancers are those at stage IIIB or IV. In the ECOG Performance Status Scale the fittest patients are rated 0-1, whereas less physically well patients are those rated 2 or higher. WHO lung cancer data from 2020 is available here.
3 Overall survival (OS) is defined as the length of time that patients are still alive from the start of treatment for a disease. In a clinical trial, measuring OS has been the gold standard measurement to see how well a new treatment works.
4 The IPSOS trial involved 453 patients with advanced stage NSCLC (Stage IIIB/IV) who were ineligible for platinum-based doublet chemotherapy, recruited at 91 hospitals in 23 countries across Asia, Europe, North America, and South America. The median age was 75 years old (age range, 33-94), with 31% aged at 80 years or older, 72% were male and 83% had ECOG PS ≥2.
Publication:
Siow Ming Lee et al.’ ‘First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised, controlled study’ will be published in The Lancet as is under strict embargo until 6 July 2023 23:30 BST / 18:30 ET.
DOI: https://doi.org/10.1016/S0140-6736(23)00774-2
About UCL – London’s Global University
UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.
Since 1826, we have championed independent thought by attracting and nurturing the world's best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.
We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.
We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.
For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.
We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.
www.ucl.ac.uk | Follow @uclnews on Twitter | Read news at www.ucl.ac.uk/news/ | Listen to UCL podcasts on SoundCloud | Find out what’s on at UCL Minds
END
Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival
2023-07-07
ELSE PRESS RELEASES FROM THIS DATE:
AI finds a way to people’s hearts (literally!)
2023-07-07
Body
Osaka, Japan - AI (artificial intelligence) may sound like a cold robotic system, but Osaka Metropolitan University scientists have shown that it can deliver heartwarming—or, more to the point, “heart-warning”—support. They unveiled an innovative use of AI that classifies cardiac functions and pinpoints valvular heart disease with unprecedented accuracy, demonstrating continued progress in merging the fields of medicine and technology to advance patient care. The results will be published in The Lancet Digital ...
Mid-life structural jawbone changes may signal women’s subsequent height loss
2023-07-07
Mid-life structural changes to the jawbone may signal subsequent height loss in women, suggests research published in the open access journal BMJ Open.
Dentists, who are likely to spot these on mouth x-rays during routine check-ups, should collaborate with patients’ doctors as this may open up opportunities for prevention, suggest the researchers.
Height loss in women tends to speed up over the age of 75 and is associated with increased risks of ill health and death, say the researchers.
Various explanations have been mooted for this loss, including progressive skeletal deformation, fallen arches in the feet and altered posture, and/or degenerative processes ...
Patient aggression towards doctors’ receptionists in general practice “serious workplace safety concern”
2023-07-07
Patient aggression towards receptionists working in general practice is a “serious workplace safety concern,” concludes a review of the available published evidence, published in the open access journal Family Medicine and Community Health.
Not only does it affect the wellbeing of the individuals concerned, but it also has operational effects by boosting levels of workplace absenteeism and the numbers of staff leaving the healthcare workforce, say the researchers.
Acts of incivility perpetrated against general practice staff, including doctors, are common, but few studies have included the perspectives of the receptionists, ...
Wildlife crossing guards
2023-07-07
Oak Ridge National Laboratory researchers developed a model framework that identifies ways to ensure wildlife can safely navigate their habitats while not unduly affecting infrastructure.
The project centered on the 32,000-acre Oak Ridge Reservation in Tennessee, home to Department of Energy facilities and several at-risk species like the four-toed salamander.
Scientists identified habitats and simulated solutions like conservation buffers and open-bottom culverts to allow safe passage for salamanders and other wildlife, which cost far less than large-scale barrier removal ...
School nurses may be crucial to reducing childhood obesity
2023-07-07
School nurses do much more than bandage scraped knees and take temperatures. A Rutgers study, published in the journal Pediatric Nursing, suggests they also may play a key role in reducing childhood obesity.
Elaine Elliott, a school nurse in Newark, teamed up with Cheryl Holly and the late Sallie Porter, professors at Rutgers University School of Nursing, to test a family-centered, school-based intervention using parents and teachers as role models for healthy eating and other behaviors.
“An important reason for the success of this program was the trust nurses have with parents ...
Leading the way to cyber safety on roads and highways
2023-07-06
A new research center led by the University of Houston is helping prevent potential cyberattacks that could threaten to impede the safe and efficient movement of people and goods in the United States and throughout the world.
CYBER-CARE – the Transportation Cybersecurity Center for Advanced Research and Education – is a U.S. Department of Transportation (USDOT) University Transportation Center (UTC), Tier 1. The center is supported by a $2 million USDOT grant for its first year with anticipated total federal funding of $10 million over five years.
“We all use transportation. Therefore, maintaining ...
Reduced levels of FKBP5 promote atrial fibrillation
2023-07-06
Atrial fibrillation (AFib) is the most common type of heart arrhythmia. This serious condition occurs when the heart beats so fast that the upper chambers of the heart quiver. This irregular heartbeat can lead to severe conditions, including heart failure, dementia and a fivefold increase in the risk of stroke.
AFib affects more than 33.5 million people worldwide, and its prevalence is increasing. Despite intense research to better understand AFib, the molecular mechanism underlying the progression of this condition remains poorly understood.
At Baylor College of Medicine, Dr. ...
Older adults experiencing social isolation are more likely to smoke
2023-07-06
Aging brings wisdom and experience; however, for some individuals getting older can also mean health challenges, loss of friends, and decreased mobility, leading to social isolation. Both the U.S. Surgeon General and the National Academy of Medicine have issued recent warnings about the growing public health concern of social isolation and loneliness and its association with premature death among the elderly.
Not having anyone to call (via phone or online) or not interacting with people in the community are forms of social isolation, which affects nearly a fifth of U.S. ...
Pennington Biomedical working to give children the best chance at a healthy life
2023-07-06
BATON ROUGE – One in five children have obesity in the U.S., and even more are considered overweight. Dr. Amanda Staiano, associate professor at Pennington Biomedical Research Center and director of the Pediatric Obesity and Health Behavior Laboratory, believes childhood obesity is at the top of the list for public health issues of this century because children with obesity are much more likely to develop heart disease, diabetes, asthma, sleep problems and other issues.
Dr. Staiano's background is in developmental psychology, and she studies how to make sure children are growing in a healthy way and in ...
Multiple factors delay timely endometriosis diagnosis, study shows
2023-07-06
Reviewing qualitative studies from the past 20 years, the researchers found a range of contributing factors including: a continuing stigma around periods; society’s normalisation of menstrual pain; and a lack of medical training about the condition.
Endometriosis, which affects 10% of women globally and 1.5 million women in the UK alone, is caused by endometrial (womb) tissue growing outside the womb. It’s extremely painful, exhausting, interferes with daily life and can lead to infertility if untreated.
The researchers found that women in the studies often weren’t sure if their pain was unusual or severe enough to seek treatment. ...